To confirm the clinical significance of NF-κB and JNK protein expression from experimentally identified candidates for predicting prognosis for patients with 5-FU treatment, we evaluated the protein expression of surgically removed specimens. A total of 79 specimens were obtained from 30 gastric and 49 colorectal cancer patients who underwent R0 resection followed by postoperative 5-FU based adjuvant chemotherapy. Immunohistochemical examinations of NF-κB and JNK on tissue microarrays (TMAs) revealed that significantly shorter time-to-relapse (TTR) in both NF-κB(+) and JNK(？) subgroups in both gastric (NF-κB(+), p = 0.0002, HR11.7. 95%CI3 3.2–43.4; JNK(？), p = 0.0302, HR4.4, 95%CI 1.2–16.6) and colon (NF-κB(+), p = 0.0038, HR36.9, 95%CI 3.2–426.0; JNK(？), p = 0.0098, HR3.2, 95%CI 1.3–7.7) cancers. These protein expression patterns also show strong discriminately power in gastric cancer patients for overall survival rate, suggesting a potential utility as prognostic or chemosensitivity markers. Baseline expression of these proteins using gastric cancer cell lines demonstrated the reciprocal patterns between NF-κB and JNK, while 5-FU exposure of these cell lines only induced NF-κB, suggesting that NF-κB plays a dominant role in the response to 5-FU. Subsequent siRNA experiments confirmed that gene knockdown of NF-κB increased 5-FU-specific sensitivity, whereas that of JNK did not affect the chemosensitivity. These results suggest that the expression of these proteins may aid in the decisions involved with adjuvant chemotherapy for gastrointestinal tract cancers.
References
[1]
Brennan DJ, O’Connor DP, Rexhepaj E, Ponten F, Gallagher WM (2010) Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat Rev Cancer 10: 605–617.
[2]
Ishida K, Nishizuka S, Noda H (2010) Characterization of clinically-used anticancer agents by quantitative cellular and molecular assay platforms. J Iwate Med Assoc 62: 363–375.
[3]
Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, et al. (2004) Integrated genomic and proteomic analyses of gene expression in Mammalian cells. Mol Cell Proteomics 3: 960–969.
[4]
Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, et al. (2009) Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 27: 872–877.
[5]
Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, et al. (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. Jama 303: 1729–1737.
[6]
Sakamoto K, Maeda S, Hikiba Y, Nakagawa H, Hayakawa Y, et al. (2009) Constitutive NF-kappaB activation in colorectal carcinoma plays a key role in angiogenesis, promoting tumor growth. Clin Cancer Res 15: 2248–2258.
[7]
Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, et al. (2011) Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer 14: 150–154.
[8]
Roxburgh C, McDonald A, Salmond J, Oien K, Anderson J, et al. (2011) Adjuvant chemotherapy for resected colon cancer: comparison of the prognostic value of tumour and patient related factors. Int J Colorectal Dis 26: 483–492.
[9]
Ross JS, Torres-Mora J, Wagle N, Jennings TA, Jones DM (2010) Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol 134: 478–490.
[10]
Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, et al. (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100: 14229–14234.
[11]
Nishizuka S, Spurrier B (2008) Experimental validation for quantitative protein network models. Curr Opin Biotechnol 19: 41–49.
[12]
Spurrier B, Ramalingam S, Nishizuka S (2008) Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc 3: 1796–1808.
[13]
Weinstein JN, Myers TG, O’Connor PM, Friend SH, Fornace AJJ, et al. (1997) An information-intensive approach to the molecular pharmacology of cancer. Science 275: 343–349.
[14]
Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, et al. (2000) A gene expression database for the molecular pharmacology of cancer. Nat Genet 24: 236–244.
[15]
Honda T, Tamura G, Endoh Y, Nishizuka S, Kawata S, et al. (2005) Expression of tumor suppressor and tumor-related proteins in differentiated carcinoma, undifferentiated carcinoma with tubular component and pure undifferentiated carcinoma of the stomach. Jpn J Clin Oncol 35: 580–586.
[16]
Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, et al. (2003) Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 63: 5243–5250.
[17]
Nishizuka S, Ramalingam S, Spurrier B, Washburn FL, Krishna R, et al. (2008) Quantitative protein network monitoring in response to DNA damage. J Proteome Res 7: 803–808.
[18]
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, et al. (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104: 263–269.
[19]
Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. (2010) Membrane transporters in drug development. Nat Rev Drug Discov 9: 215–236.
[20]
Grem JL, Danenberg KD, Behan K, Parr A, Young L, et al. (2001) Thymidine kinase, thymidylate synthase, and dihydropyrimidine dehydrogenase profiles of cell lines of the National Cancer Institute’s Anticancer Drug Screen. Clin Cancer Res 7: 999–1009.
[21]
Matsuyama R, Togo S, Shimizu D, Momiyama N, Ishikawa T, et al. (2006) Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer 119: 406–413.
[22]
Kamata H, Honda S, Maeda S, Chang L, Hirata H, et al. (2005) Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649–661.
[23]
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, et al. (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357: 1810–1820.
[24]
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, et al. (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345: 725–730.
[25]
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11–20.
[26]
O’Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, et al. (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16: 295–300.
[27]
Aoyama T, Yoshikawa T, Watanabe T, Hayashi T, Ogata T, et al.. (2011) Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1. Gastric Cancer.
[28]
Ito N, Morita T, Nakamura F, Konn M (1997) Distant metastasis of colorectal cancer that extend into only muscularis propria -a clinico pathological study-. Jpn J Gastroenterol Surg 30: 741–747.
[29]
Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. (2007) Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370: 2020–2029.
[30]
Uen YH, Lu CY, Tsai HL, Yu FJ, Huang MY, et al. (2008) Persistent presence of postoperative circulating tumor cells is a poor prognostic factor for patients with stage I-III colorectal cancer after curative resection. Ann Surg Oncol 15: 2120–2128.
[31]
Cunningham D, Starling N (2007) Adjuvant chemotherapy of colorectal cancer. Lancet 370: 1980–1981.
[32]
Bednarski BK, Ding X, Coombe K, Baldwin AS, Kim HJ (2008) Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin. Mol Cancer Ther 7: 1827–1835.
[33]
Bourgarel-Rey V, Vallee S, Rimet O, Champion S, Braguer D, et al. (2001) Involvement of nuclear factor kappaB in c-Myc induction by tubulin polymerization inhibitors. Mol Pharmacol 59: 1165–1170.
[34]
Nakanishi C, Toi M (2005) Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297–309.
[35]
Voboril R, Hochwald SN, Li J, Brank A, Weberova J, et al. (2004) Inhibition of NF-kappa B augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J Surg Res 120: 178–188.
[36]
Wang CY, Cusack JC Jr, Liu R, Baldwin ASJ (1999) Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412–417.
[37]
Uetsuka H, Haisa M, Kimura M, Gunduz M, Kaneda Y, et al. (2003) Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp Cell Res 289: 27–35.
[38]
Voboril R, Weberova-Voborilova J (2007) Sensitization of colorectal cancer cells to irradiation by IL-4 and IL-10 is associated with inhibition of NF-kappaB. Neoplasma 54: 495–502.
[39]
Levidou G, Korkolopoulou P, Nikiteas N, Tzanakis N, Thymara I, et al. (2007) Expression of nuclear factor kappaB in human gastric carcinoma: relationship with I kappaB a and prognostic significance. Virchows Arch 450: 519–527.
[40]
Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, et al. (2001) Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 7: 4136–4142.
[41]
Yamanaka N, Sasaki N, Tasaki A, Nakashima H, Kubo M, et al. (2004) Nuclear factor-kappaB p65 is a prognostic indicator in gastric carcinoma. Anticancer Res 24: 1071–1075.
[42]
Kojima M, Morisaki T, Sasaki N, Nakano K, Mibu R, et al. (2004) Increased nuclear factor-kB activation in human colorectal carcinoma and its correlation with tumor progression. Anticancer Res 24: 675–681.
[43]
Scartozzi M, Bearzi I, Pierantoni C, Mandolesi A, Loupakis F, et al. (2007) Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy. J Clin Oncol 25: 3930–3935.
[44]
Papa S, Bubici C, Zazzeroni F, Pham CG, Kuntzen C, et al. (2006) The NF-kappaB-mediated control of the JNK cascade in the antagonism of programmed cell death in health and disease. Cell Death Differ 13: 712–729.
[45]
Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537–549.
[46]
Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G (2004) NF-kappaB and JNK: an intricate affair. Cell Cycle 3: 1524–1529.
[47]
Karin M, Greten FR (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5: 749–759.
[48]
Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, et al. (2004) Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 119: 529–542.
[49]
Tang G, Minemoto Y, Dibling B, Purcell NH, Li Z, et al. (2001) Inhibition of JNK activation through NF-kappaB target genes. Nature 414: 313–317.
[50]
Lind DS, Hochwald SN, Malaty J, Rekkas S, Hebig P, et al. (2001) Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery 130: 363–369.
[51]
Krueger S, Hundertmark T, Kalinski T, Peitz U, Wex T, et al. (2006) Helicobacter pylori encoding the pathogenicity island activates matrix metalloproteinase 1 in gastric epithelial cells via JNK and ERK. J Biol Chem 281: 2868–2875.
[52]
Shembade N, Harhaj NS, Liebl DJ, Harhaj EW (2007) Essential role for TAX1BP1 in the termination of TNF-alpha-, IL-1- and LPS-mediated NF-kappaB and JNK signaling. EMBO J 26: 3910–3922.
